Journal of Cancer Metastasis and Treatment最新文献

Thermal ablation of metastatic disease to the musculoskeletal system 热消融转移到肌肉骨骼系统的疾病

Journal of Cancer Metastasis and Treatment Pub Date : 2023-10-25 DOI: 10.20517/2394-4722.2023.26

Erwin Xia, Ambrose J. Huang

{"title":"Thermal ablation of metastatic disease to the musculoskeletal system","authors":"Erwin Xia, Ambrose J. Huang","doi":"10.20517/2394-4722.2023.26","DOIUrl":"https://doi.org/10.20517/2394-4722.2023.26","url":null,"abstract":"A variety of indications have been published regarding the use of percutaneous thermal ablation for treating tumors of the musculoskeletal system, including bone and soft tissue lesions, benign and malignant lesions, and primary and metastatic tumors. In the appropriately selected patient, the advantages of percutaneous thermal ablation include decreased morbidity, decreased cost, and shorter hospitalization stays compared to surgery. The number of different thermal ablation modalities is increasing, and each modality has its advantages and disadvantages. Studies directly comparing the effectiveness of the various thermal ablation modalities are sparse, however, so the choice of ablation modality often depends on availability, user preference, and local expertise. Although the list of uses for percutaneous thermal ablation is ever-expanding, in this article, we will discuss the two most well-established indications, which are palliation of pain attributed to bone and soft tissue metastases and local control of oligometastatic disease. Numerous clinical trials have shown percutaneous thermal ablation to be an effective method of palliating pain due to bone and soft tissue metastases and of achieving local control in the setting of oligometastatic disease with low rates of complication.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134971975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Does delaying surgery following induction chemotherapy compromise survival in patients with mesothelioma? 诱导化疗后延迟手术是否会影响间皮瘤患者的生存?

Journal of Cancer Metastasis and Treatment Pub Date : 2023-09-15 DOI: 10.20517/2394-4722.2023.57

Lye-Yeng Wong, Ioana Baiu, Matthew Leipzig, Ashley Titan, Douglas Z. Liou, Natalie Lui, Mark Berry, Joseph B. Shrager, Leah Backhus

{"title":"Does delaying surgery following induction chemotherapy compromise survival in patients with mesothelioma?","authors":"Lye-Yeng Wong, Ioana Baiu, Matthew Leipzig, Ashley Titan, Douglas Z. Liou, Natalie Lui, Mark Berry, Joseph B. Shrager, Leah Backhus","doi":"10.20517/2394-4722.2023.57","DOIUrl":"https://doi.org/10.20517/2394-4722.2023.57","url":null,"abstract":"Objective: The ideal time interval between induction chemotherapy and surgery and the impact on cancer mortality in patients with mesothelioma remains unclear. Methods: We queried the National Cancer Database (2004-2017) for patients with favorable prognostic factors considered for surgery. Immediate surgery was performed within 3 months following the start of induction chemotherapy, while delayed surgery was defined as surgery performed later than 3 months. We compared both groups to those who did not have an operation despite being surgical candidates, as well as to those who were treated with surgery only. Overall mortality was assessed using Cox proportional hazard models adjusting for covariates. Results: A total of 4,294 patients were included, with the majority of patients undergoing induction chemotherapy followed by no surgery (3,370, 78%). The proportion of patients undergoing both immediate and delayed surgery increased over the last decade, but delayed surgery continued to be more common. There were no significant differences in baseline characteristics between the immediate and delayed surgery groups. Higher comorbidity scores were significantly associated with an increased risk of death on multivariable analysis, but the timing of surgery was not. This held true with a sensitivity analysis using 6 months as the definition of delayed surgery. Conclusions: This study shows that delaying surgery following induction chemotherapy does not compromise overall survival in patients with mesothelioma.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135436722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An update on clinical trials for chemoprevention of human skin cancer. 人类皮肤癌症化学预防临床试验的最新进展。

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 Epub Date: 2023-02-27 DOI: 10.20517/2394-4722.2022.99

Victoria Jiminez, Nabiha Yusuf

{"title":"An update on clinical trials for chemoprevention of human skin cancer.","authors":"Victoria Jiminez, Nabiha Yusuf","doi":"10.20517/2394-4722.2022.99","DOIUrl":"https://doi.org/10.20517/2394-4722.2022.99","url":null,"abstract":"The pathophysiology of skin cancer is complex, with multiple factors contributing to its development. The proactive treatment of skin cancer has been investigated in the form of chemoprevention of cutaneous malignancies in clinical trials. Chemoprevention is the use of natural or pharmacologic agents that prevent or reverse skin cancer development. Multiple trials have arisen over the past decades to explore the efficacy of specific agents to halt the progression of UV radiation damage. This comprehensive review article aims to assess clinical trials performed with chemopreventive agents for melanoma and nonmelanoma skin cancers. The following compounds were most often used in these trials: nicotinamide, retinoids, polyphenolic antioxidants, COX-2 selective inhibitors, non-steroidal anti-inflammatory drugs, difluoromethylornithine, and 5-fluorouracil. Many agents show promise in their ability to prevent nonmelanoma skin cancer formation, with few melanoma trials demonstrating efficacy. The chemoprevention efforts aimed at skin cancer are complex; current and future trials will be instrumental in identifying therapeutic agents that pose efficacy in halting cancer development and assessing whether long-term administration is tolerable.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41168484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dissecting molecular mechanisms of immune microenvironment dysfunction in multiple myeloma and precursor conditions. 剖析多发性骨髓瘤和前体疾病免疫微环境功能失调的分子机制。

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 Epub Date: 2023-05-16 DOI: 10.20517/2394-4722.2022.110

Maria Moscvin, Benjamin Evans, Giada Bianchi

{"title":"Dissecting molecular mechanisms of immune microenvironment dysfunction in multiple myeloma and precursor conditions.","authors":"Maria Moscvin, Benjamin Evans, Giada Bianchi","doi":"10.20517/2394-4722.2022.110","DOIUrl":"10.20517/2394-4722.2022.110","url":null,"abstract":"Multiple myeloma (MM) is a disease of clonally differentiated plasma cells. MM is almost always preceded by precursor conditions, monoclonal gammopathy of unknown significance (MGUS), and smoldering MM (SMM) through largely unknown molecular events. Genetic alterations of the malignant plasma cells play a critical role in patient clinical outcomes. Del(17p), t(4;14), and additional chromosomal alterations such as del(1p32), gain(1q) and MYC translocations are involved in active MM evolution. Interestingly, these genetic alterations appear strikingly similar in transformed plasma cell (PC) clones from MGUS, SMM, and MM stages. Recent studies show that effectors of the innate and adaptive immune response show marked dysfunction and skewing towards a tolerant environment that favors disease progression. The MM myeloid compartment is characterized by myeloid-derived suppressor cells (MDSCs), dendritic cells as well as M2-like phenotype macrophages that promote immune evasion. Major deregulations are found in the lymphoid compartment as well, with skewing towards immune tolerant Th17 and Treg and inhibition of CD8+ cytotoxic and CD4+ activated effector T cells. In summary, this review will provide an overview of the complex cross-talk between MM plasma cells and immune cells in the microenvironment and the molecular mechanisms promoting progression from precursor states to full-blown myeloma.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10783205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67652412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas. 弥漫性胸膜间皮瘤患者靶向治疗方法的过去、现在和未来。

IF 1.4

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 Epub Date: 2023-05-30 DOI: 10.20517/2394-4722.2022.140

Michael Offin, Bailey Fitzgerald, Marjorie G Zauderer, Deborah Doroshow

引用次数: 0

Clinical resistance predictors to first-line VEGFR-TKI monotherapy for metastatic renal cell carcinoma: a retrospective multicenter real-life case series 转移性肾细胞癌一线VEGFR-TKI单药治疗的临床耐药预测因素:回顾性多中心真实病例系列

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 DOI: 10.20517/2394-4722.2023.41

Pezzicoli Gaetano, Quaglini Silvana, Tibollo Valentina, Bersanelli Melissa, Porta Camillo, Rizzo Mimma

{"title":"Clinical resistance predictors to first-line VEGFR-TKI monotherapy for metastatic renal cell carcinoma: a retrospective multicenter real-life case series","authors":"Pezzicoli Gaetano, Quaglini Silvana, Tibollo Valentina, Bersanelli Melissa, Porta Camillo, Rizzo Mimma","doi":"10.20517/2394-4722.2023.41","DOIUrl":"https://doi.org/10.20517/2394-4722.2023.41","url":null,"abstract":"Aim: For many years, systemic treatment of metastatic Renal Cell Carcinoma (mRCC) was based on sequential targeted agent monotherapies. In this real-life case series, we evaluated easily accessible clinical factors useful for disease course prediction. Methods: We exploited patients' clinical pathological characteristics and systemic treatment outcomes in a real-world population of 365 mRCC patients who received sequential monotherapies in the targeted therapy era, and we identified an early progressors subpopulation, resistant to first-line VEGFR-TKI monotherapy in less than 6 months. Results: Early progressors (n = 124) show a far worse OS compared with patients progressing beyond the sixthmonth of therapy (13.5 vs. 44.8 months, P-value < 0.0001, HR = 0.41, 95%CI: 0.29-0.53). However, these patients did not show far worse performance in second and third-line settings compared to first-line responders. In the univariate analysis, IMDC risk class, sarcomatoid features, and Systemic Inflammation Index (SII) were correlated with first-line therapy Progression-Free Survival (PFS1). In multivariate analysis, variables correlated with first-line outcome were IMDC risk class, histotype, and number of metastatic sites at the diagnosis. Conclusion: Real-world data can contribute to developing easy-to-use prognostic factors associated with refractory disease that could support clinicians in identifying the most appropriate treatment strategy for each patient.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136054151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Two rare cancers of the exocrine pancreas: to treat or not to treat like ductal adenocarcinoma? 两种罕见的外分泌胰腺癌:像导管腺癌一样治疗还是不治疗?

IF 1.9

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 DOI: 10.20517/2394-4722.2022.106

Nebojsa Skorupan, Shadin Ghabra, J Alberto Maldonado, Yang Zhang, Christine Alewine

{"title":"Two rare cancers of the exocrine pancreas: to treat or not to treat like ductal adenocarcinoma?","authors":"Nebojsa Skorupan, Shadin Ghabra, J Alberto Maldonado, Yang Zhang, Christine Alewine","doi":"10.20517/2394-4722.2022.106","DOIUrl":"https://doi.org/10.20517/2394-4722.2022.106","url":null,"abstract":"Pancreatic cancer is an aggressive malignancy with increasing incidence. Pancreatic ductal adenocarcinoma (PDAC) accounts for > 90% of pancreatic cancer diagnoses, while other exocrine tumors are much rarer. In this review, we have focused on two rare cancers of the exocrine pancreas: adenosquamous carcinoma of the pancreas (ASCP) and pancreatic acinar cell carcinoma (PACC). The latest findings regarding their cellular and molecular pathology, clinical characteristics, prognosis, and clinical management are discussed. New genetic and transcriptomic data suggest that ASCP is related to or overlaps with the basal transcriptomic subtype of PDAC. These tumors are highly aggressive and driven by activated KRAS and MYC expression. Clinical outcomes remain poor and effective treatments are limited. PACC has no morphologic or genetic resemblance to PDAC and more favorable outcomes. Early stage PACC patients have improved survival with surgical resection and patients with advanced disease benefit most from platinum- or fluoropyrimidine-containing chemotherapy. Frequency of actionable genetic mutations is high in this disease and case reports suggest good outcomes when matched therapy is given. Dedicated clinical studies examining ASCP and PACC are limited and difficult to accrue. Further research is needed to define optimal clinical management for these rare diseases.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":"9 ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400043/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10302300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Role of epithelial-mesenchymal transition factor SNAI1 and its targets in ovarian cancer aggressiveness. 上皮-间质转化因子SNAI1及其靶点在卵巢癌侵袭性中的作用

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 Epub Date: 2023-06-30 DOI: 10.20517/2394-4722.2023.34

Tise Suzuki, Ashlyn Conant, Casey Curow, Audrey Alexander, Yevgeniya Ioffe, Juli J Unternaehrer

引用次数: 1

Chemoprevention of neuroblastoma: progress and promise beyond uncertainties. 神经母细胞瘤的化学预防：不确定因素之外的进展与希望。

IF 1.9

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 Epub Date: 2023-03-31 DOI: 10.20517/2394-4722.2022.40

Natarajan Aravindan, Mohan Natarajan, Dinesh Babu Somasundaram, Sheeja Aravindan

{"title":"Chemoprevention of neuroblastoma: progress and promise beyond uncertainties.","authors":"Natarajan Aravindan, Mohan Natarajan, Dinesh Babu Somasundaram, Sheeja Aravindan","doi":"10.20517/2394-4722.2022.40","DOIUrl":"10.20517/2394-4722.2022.40","url":null,"abstract":"Neuroblastoma is the most common extracranial solid tumor in children and comprises one-tenth of all childhood cancer deaths. The current clinical therapy for this deadly disease is multimodal, involving an induction phase with alternating regimens of high-dose chemotherapeutic drugs and load reduction surgery; a consolidation phase with more intensive chemotherapy, radiotherapy, and stem cell transplant; and a maintenance phase with immunotherapy and immune-activating cytokine treatment. Despite such intensive treatment, children with neuroblastoma have unacceptable life quality and survival, warranting preventive measures to regulate the cellular functions that orchestrate tumor progression, therapy resistance, metastasis, and tumor relapse/recurrence. Globally, active efforts are underway to identify novel chemopreventive agents, define their mechanism(s) of action, and assess their clinical benefit. Some chemoprevention strategies (e.g., retinoids, difluoromethylornithine) have already been adopted clinically as part of maintenance phase therapy. Several agents are in the pipeline, while many others are in preclinical characterization. Here we review the classes of chemopreventive agents investigated for neuroblastoma, including cellular events targeted, mode(s) of action, and the level of development. Our review: (i) highlights the pressing need for new and improved chemopreventive strategies for progressive neuroblastoma; (ii) lists the emerging classes of chemopreventive agents for neuroblastoma; and (iii) recognizes the relevance of targeting dynamically evolving hallmark functions of tumor evolution (e.g., survival, differentiation, lineage transformation). With recent gains in the understanding of tumor evolution processes and preclinical and clinical efforts, it is our strong opinion that effective chemopreventive strategies for aggressive neuroblastoma are a near reality.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":"1 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10798790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67652086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune responses elicited by ssRNA(-) oncolytic viruses in the host and in the tumor microenvironment. ssRNA(-)溶瘤病毒在宿主和肿瘤微环境中引发的免疫应答。

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 Epub Date: 2023-04-04 DOI: 10.20517/2394-4722.2022.92

Yonina Bykov, Gloria Dawodu, Aryana Javaheri, Adolfo Garcia-Sastre, Sara Cuadrado-Castano

{"title":"Immune responses elicited by ssRNA(-) oncolytic viruses in the host and in the tumor microenvironment.","authors":"Yonina Bykov, Gloria Dawodu, Aryana Javaheri, Adolfo Garcia-Sastre, Sara Cuadrado-Castano","doi":"10.20517/2394-4722.2022.92","DOIUrl":"10.20517/2394-4722.2022.92","url":null,"abstract":"Oncolytic viruses (OVs) are at the forefront of biologicals for cancer treatment. They represent a diverse landscape of naturally occurring viral strains and genetically modified viruses that, either as single agents or as part of combination therapies, are being evaluated in preclinical and clinical settings. As the field gains momentum, the research on OVs has been shifting efforts to expand our understanding of the complex interplay between the virus, the tumor and the immune system, with the aim of rationally designing more efficient therapeutic interventions. Nowadays, the potential of an OV platform is no longer defined exclusively by the targeted replication and cancer cell killing capacities of the virus, but by its contribution as an immunostimulator, triggering the transformation of the immunosuppressive tumor microenvironment (TME) into a place where innate and adaptive immunity players can efficiently engage and lead the development of tumor-specific long-term memory responses. Here we review the immune mechanisms and host responses induced by ssRNA(-) (negative-sense single-stranded RNA) viruses as OV platforms. We focus on two ssRNA(-) OV candidates: Newcastle disease virus (NDV), an avian paramyxovirus with one of the longest histories of utilization as an OV, and influenza A (IAV) virus, a well-characterized human pathogen with extraordinary immunostimulatory capacities that is steadily advancing as an OV candidate through the development of recombinant IAV attenuated platforms.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67652994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0